Condition: Cystic Fibrosis · Sponsor: Hôpital Necker-Enfants Malades
The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.
This description comes directly from the study's public registry record.
Isabelle Sermet, MD, PhD · 33 1 44 49 48 87 · isabelle.sermet@aphp.fr
Jean-Louis Pérignon, MD, PhD · jean-louis.perignon@aphp.fr
Always discuss trial participation with your own doctor first.
| Necker Hospital | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02965326